This clinical trial is focused on studying treatments for prostate cancer, specifically in cases where the cancer is localized but at high risk of coming back. The study involves the use of several medications that block androgen receptors, which are proteins in the body that can promote the growth of prostate cancer cells. The medications being tested include Enzalutamide (known by the brand name Xtandi), Nilutamide (known as Anandron), Bicalutamide (known as Casodex), and Flutamide. These medications are taken orally in the form of tablets or capsules.

The purpose of the study is to determine the effects of these treatments on the time patients remain free from cancer spreading to other parts of the body or dying from any cause. Participants in the study will receive one of these medications, and some may receive a placebo. The study will also involve radiation therapy as part of the treatment plan. The trial will last for a period of time, during which participants will be monitored regularly to assess their health and the effectiveness of the treatment.

Throughout the study, researchers will collect information on various outcomes, such as overall survival, the time until the cancer progresses, and the safety of the treatments. They will also evaluate the quality of life of participants and the cost-effectiveness of the treatments. This information will help in understanding how well these medications work in treating high-risk localized prostate cancer and their impact on patients’ lives.